GSK acquires Reliant in move to boost cardio franchise

Share this article:

In a move to bolster its cardiovascular product line, GlaxoSmithKline has announced plans to purchase New Jersey-based Reliant Pharmaceuticals for $1.65 billion in cash.

The acquisition will strengthen GSK's cardiovascular drugs area anchored by its hypertension and congestive heart failure treatment Coreg, which sold $1.1 billion in the first nine months of 2007.

The acquisition adds Reliant's triglyceride-lowerer Lovaza which had sales of $206 million in the first nine months of 2007. Reliant's other drugs include Dyna Circ and InnoPran XL to treat high blood pressure and Rythmol SR for abnormal heartbeats.

Privately held Reliant reported sales growth of 62% in the first nine months of 2007, to $341 million. The company has 1,000 employees, 800 of them in sales, a GSK spokesman said in a published report.

Reliant's CEO Bradley Sheares said in a statement that his sales force has “demonstrated their worth in building a formidable Lovaza franchise in less than 24 months.”

The acquisition is subject to approval by the US Federal Trade Commission and is expected to conclude before year-end.

Share this article:
close

Next Article in News

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...